Sales of
-Downgrade reflects problems in distribution, largely in
-Material uplift required in second half revenue to meet guidance
-Strong revenue growth continues in
Just as
The main contributor to the weakness stems from the Australian distributor and daigou (purchasing in
Morgans was not surprised Australian retail daigou has been affected, given reduced tourism from
Nevertheless, the broker believes recent weakness in the share price is a buying opportunity in a high-quality growth company, upgrading to Add from Hold, and also flags Singles Day on
Macquarie agrees, should the impact be temporary and the implied demand materialise, the stock offers an opportunity, although suspects uncertainty will overhang until proven otherwise. If the stock becomes too cheap the broker anticipates some backstop to valuation in terms of potential M&A.
The broker points out in periods in which earnings uncertainty existed such as late 2018 and late 2019,
Maiden FY21 revenue guidance of NZ$1.8-1.9bn is lower than many brokers expected and includes a particularly weak first half performance, with guidance reduced to NZ$725m-775m because of lower daigou-related infant formula sales.
Margins
Moreover, the breadth and value of insider selling recently, as a percentage of overall shareholdings sold, has also rumbled investors for a while and this is now amplified following the disappointing update.
Credit Suisse re-bases FY21-23 estimates to factor in the disruption to corporate daigou and maintains operating margins, noting the company has also indicated more favourable procurement costs from
Hence, Macquarie is more confident in the operating earnings margin outlook, noting some reductions in discretionary expenditure and a small unwinding of the inventory provision taken at the FY20 result. The strong margin profile and potential upside, should the daigou disruption be temporary, is likely to ensure a more normal trading period in FY22 in the broker's view.
Daigou
The Australian retail daigou channel via grocery and pharmacy chains has been weak since February because of the pandemic. Hence, the company is actively managing inventory, although infant formula demand through direct
Still,
Management expectations of a recovery in the second half include some improvement in daigou but no material re-stocking of the channel. A robust performance across the other aspect of the business is countering the impact somewhat, such as liquid milk sales, which are strong in
Morgan Stanley also highlights that the China MBS (mother & baby stores) channel, which is 24% of FY20 infant formula sales, experienced revenue growth in August of around 77%, albeit this mostly reflected same-store sales growth rather than new distribution.
The database has four Buy ratings and three Sell for
FNArena is proud about its track record and past achievements: Ten Years On
All material published by
© 2020 Acquisdata Pty Ltd., source